A Study of Emapalumab for Pediatric Aplastic Anemia
NCT06430788
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Aplastic Anemia
- Cytopenia
- Hypocellular Marrow
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 0 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- December 17, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, NY
Ohio · 1
- Cincinnati Children's Hospital Medical Center (Data collection only) · Cincinnati, OH
Pennsylvania · 1
- Children's Hospital of Philadelphia (Data Collection AND Specimen Analysis) · Philadelphia, PA
Virginia · 1
- Virginia Commonwealth University (Data Collection Only ) · Richmond, VA
Wisconsin · 1
- Children's Hospital of Wisconsin (Data Collection Only) · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.